Antihypertensive efficacy and tolerability of two fixed- dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension : An 8-week, randomized, double-blind, parallel-group trial
- Author
- LACOURCIERE, Yves1 ; POIRIER, Luc1 ; HEBERT, Daniel2 ; ASSOULINE, Linda2 ; STOLT, Pelle3 ; REHEL, Bonita2 ; KHDER, Yasser3
[1] Centre Hospitalier de l'Université Laval (CHUQ), Sainte-Foy, Québec, Canada
[2] Novartis Pharmaceuticals Canada Inc, Dorval, Québec, Canada
[3] Novartis Pharmaceuticals AG, Basel, Switzerland - Source
Clinical therapeutics. 2005, Vol 27, Num 7, pp 1013-1021, 9 p ; ref : 19 ref
- ISSN
- 0149-2918
- Scientific domain
- Pharmacology drugs
- Publisher
- Excerpta Medica, Belle Mead, NJ
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- systolic hypertension tolerability valsartan + HCTZ valsartan
- Keyword (fr)
- Antihypertenseur Diurétique Etude double insu Homme Hydrochlorothiazide Hypertension artérielle systolique Randomisation Toxicité Valsartan Benzothiadiazine dérivé Valine dérivé Aminoacide Angiotensine II Antagoniste angiotensine Biphényle dérivé Hormone peptide Octapeptide Récepteur angiotensine AT1 Sulfamides Système renin angiotensine Thiazide Tétrazole dérivé
- Keyword (en)
- Antihypertensive agent Diuretic Double blind study Human Hydrochlorothiazide Systolic hypertension Randomization Toxicity Valsartan Aminoacid Angiotensin II Angiotensin antagonist Biphenyl derivatives Peptide hormone Octapeptide AT1 angiotensin receptor Sulfanilamide derivatives Renin angiotensin system Thiazide Tetrazole derivatives
- Keyword (es)
- Antihipertensivo Diurético Estudio doble ciego Hombre Hidroclorotiazida Hipertensión arterial sistólica Aleatorización Toxicidad Valsartán Aminoácido Angiotensina II Antagonista angiotensina Bifenilo derivado Hormona péptido Octapéptido Receptor angiotensina AT1 Sulfamidas Sistema renin angiotensina Tiazida Tetrazol derivado
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments
- Discipline
- General pharmacology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17039663
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/j.clinthera.2005.07.010 
https://dx.doi.org/10.1016/j.clinthera.2005.07.010
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:31:\"10.1016\/j.clinthera.2005.07.010\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:259:\"Antihypertensive efficacy and tolerability of two fixed- dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension : An 8-week, randomized, double-blind, parallel-group trial\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Clinical therapeutics\";s:9:\"\u0000*\u0000stitle\";s:10:\"Clin. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1013\";s:8:\"\u0000*\u0000epage\";s:4:\"1021\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-2918\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"LACOURCIERE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Yves\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:12:\"POIRIER, Luc\";i:1;s:14:\"HEBERT, Daniel\";i:2;s:16:\"ASSOULINE, Linda\";i:3;s:12:\"STOLT, Pelle\";i:4;s:13:\"REHEL, Bonita\";i:5;s:13:\"KHDER, Yasser\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:259:\"Antihypertensive efficacy and tolerability of two fixed- dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension : An 8-week, randomized, double-blind, parallel-group trial\";s:8:\"\u0000*\u0000place\";s:14:\"Belle Mead, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Excerpta Medica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:31:\"10.1016\/j.clinthera.2005.07.010\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:259:\"Antihypertensive efficacy and tolerability of two fixed- dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension : An 8-week, randomized, double-blind, parallel-group trial\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Clinical therapeutics\";s:9:\"\u0000*\u0000stitle\";s:10:\"Clin. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1013\";s:8:\"\u0000*\u0000epage\";s:4:\"1021\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-2918\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"LACOURCIERE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Yves\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:12:\"POIRIER, Luc\";i:1;s:14:\"HEBERT, Daniel\";i:2;s:16:\"ASSOULINE, Linda\";i:3;s:12:\"STOLT, Pelle\";i:4;s:13:\"REHEL, Bonita\";i:5;s:13:\"KHDER, Yasser\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:259:\"Antihypertensive efficacy and tolerability of two fixed- dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension : An 8-week, randomized, double-blind, parallel-group trial\";s:8:\"\u0000*\u0000place\";s:14:\"Belle Mead, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Excerpta Medica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:31:\"10.1016\/j.clinthera.2005.07.010\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:31:\"10.1016\/j.clinthera.2005.07.010\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:259:\"Antihypertensive efficacy and tolerability of two fixed- dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension : An 8-week, randomized, double-blind, parallel-group trial\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Clinical therapeutics\";s:9:\"\u0000*\u0000stitle\";s:10:\"Clin. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1013\";s:8:\"\u0000*\u0000epage\";s:4:\"1021\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-2918\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"LACOURCIERE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Yves\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:12:\"POIRIER, Luc\";i:1;s:14:\"HEBERT, Daniel\";i:2;s:16:\"ASSOULINE, Linda\";i:3;s:12:\"STOLT, Pelle\";i:4;s:13:\"REHEL, Bonita\";i:5;s:13:\"KHDER, Yasser\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:259:\"Antihypertensive efficacy and tolerability of two fixed- dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension : An 8-week, randomized, double-blind, parallel-group trial\";s:8:\"\u0000*\u0000place\";s:14:\"Belle Mead, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Excerpta Medica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:31:\"10.1016\/j.clinthera.2005.07.010\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:259:\"Antihypertensive efficacy and tolerability of two fixed- dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension : An 8-week, randomized, double-blind, parallel-group trial\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Clinical therapeutics\";s:9:\"\u0000*\u0000stitle\";s:10:\"Clin. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1013\";s:8:\"\u0000*\u0000epage\";s:4:\"1021\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-2918\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"LACOURCIERE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Yves\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:12:\"POIRIER, Luc\";i:1;s:14:\"HEBERT, Daniel\";i:2;s:16:\"ASSOULINE, Linda\";i:3;s:12:\"STOLT, Pelle\";i:4;s:13:\"REHEL, Bonita\";i:5;s:13:\"KHDER, Yasser\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:259:\"Antihypertensive efficacy and tolerability of two fixed- dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension : An 8-week, randomized, double-blind, parallel-group trial\";s:8:\"\u0000*\u0000place\";s:14:\"Belle Mead, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Excerpta Medica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:31:\"10.1016\/j.clinthera.2005.07.010\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:259:\"Antihypertensive efficacy and tolerability of two fixed- dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension : An 8-week, randomized, double-blind, parallel-group trial\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Clinical therapeutics\";s:9:\"\u0000*\u0000stitle\";s:10:\"Clin. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2005\";s:9:\"\u0000*\u0000volume\";s:2:\"27\";s:8:\"\u0000*\u0000issue\";s:1:\"7\";s:8:\"\u0000*\u0000spage\";s:4:\"1013\";s:8:\"\u0000*\u0000epage\";s:4:\"1021\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0149-2918\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"LACOURCIERE\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Yves\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:6:{i:0;s:12:\"POIRIER, Luc\";i:1;s:14:\"HEBERT, Daniel\";i:2;s:16:\"ASSOULINE, Linda\";i:3;s:12:\"STOLT, Pelle\";i:4;s:13:\"REHEL, Bonita\";i:5;s:13:\"KHDER, Yasser\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:259:\"Antihypertensive efficacy and tolerability of two fixed- dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension : An 8-week, randomized, double-blind, parallel-group trial\";s:8:\"\u0000*\u0000place\";s:14:\"Belle Mead, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Excerpta Medica\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
